Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.43 |
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CCR9 | P51686 | 5/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938470 | 1.00 | P2RX3 (0.43) | P2RX3GNRHRTP53SMN1; SMN2KCNH2 | |
| SCHEMBL4934802 | 0.90 | GNRHR (0.43) | P2RX3GNRHRTP53SMN1; SMN2ACE | |
| SCHEMBL4933601 | 0.88 | TP53 (0.54) | TP53SMN1; SMN2POLBPTPN1PPARG | |
| SCHEMBL4933609 | 0.88 | TP53 (0.54) | TP53SMN1; SMN2POLBPTPN1PPARG | |
| SCHEMBL4938061 | 0.88 | GNRHR (0.40) | GNRHRTP53SMN1; SMN2POLBPPARG | |
| SCHEMBL4938075 | 0.88 | GNRHR (0.40) | GNRHRTP53SMN1; SMN2POLBPPARG | |
| SCHEMBL4938378 | 0.83 | GNRHR (0.43) | P2RX3GNRHRPPARAPPARGSCN9A | |
| SCHEMBL4938392 | 0.83 | GNRHR (0.43) | P2RX3GNRHRPPARAPPARGSCN9A | |
| SCHEMBL4934976 | 0.82 | SCN9A (0.42) | GNRHRPPARAPPARGSCN9ACYP3A4 | |
| SCHEMBL4934989 | 0.82 | SCN9A (0.42) | GNRHRPPARAPPARGSCN9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | P2RX3 4797/4885GNRHR 4023/4885TP53 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.